PRKG2 Antibody

1. L-Arginine is a potential alternative to PKG II activation. PMID: 29401205
2. Comparative analysis of the backbone hydrogen/deuterium exchange patterns in PKG II:8-pCPT-cGMP and previously reported PKG Ibeta:cGMP XN structures suggests that the ability of these agonists to activate PKG is related to how effectively they quench dynamics of the cyclic nucleotide binding pocket and the surrounding regions. PMID: 29517905
3. the results indicated that PKG II could block c-Met activation via phosphorylating Ser985 PMID: 27147579
4. PKG II inhibits EGFinduced activation of HER2 through binding with and causing threonine 686 phosphorylation of this oncogenic protein. PMID: 26676300
5. The C-terminal cyclic nucleotide binding (CNB-B) domain of cGMP-dependent protein kinase II binds cGMP with higher affinity and selectivity when compared with its N-terminal CNB (CNB-A) domain. PMID: 26769964
6. Han Chinese patients with rs10033237 polymorphism of cGKII/PRKG2 gene are more likely to suffer from gout. PMID: 25688884
7. Our replication study suggests that cGKII is not involved in gout susceptibility. PMID: 24882840
8. we determined a crystal structure of the PKG II LZ-Rab11b complex. The PKG II LZ domain presents a mostly nonpolar surface onto which Rab11b docks, through van der Waals interactions PMID: 25070890
9. PKGII inhibits RhoA activity by binding to this small GTPase and causing phosphorylation at its Ser188 site. PMID: 24549567
10. PKG II also inhibits the activation of the EGFR caused by diverse ligands of the receptor. PMID: 24534906
11. type II cGMPdependent protein kinase prevented the EGF-induced phosphorylation/activation of ERK and JNK, but not the phosphorylation of p38MAPK induced by EGF. PMID: 22940826
12. Downregulation of PKG2 was associated with malignant and benign breast tumors. PMID: 22791569
13. The work presented here demonstrates a novel antiproliferative and prodifferentiation role for PKG2 in the colon. PMID: 22556146
14. The results suggest that PKGII inhibits EGF-induced MAPK/JNK-mediated signal transduction and further confirmed that PKGII can block the activation of EGFR. PMID: 22427012
15. PKG II inhibits the proliferation of gastric cancer cells through blocking EGF-triggered MAPK signal transduction. PMID: 22012247
16. As an addition to PRKG2 and RASGEFIB genes, we propose to include BMP3 gene as the principal determinant of the observed common phenotype. PMID: 22303795
17. Inhibition of cGMP-dependent protein kinase II by its own splice isoform PMID: 12054676
18. results show that the fast phase of autophosphorylation of cGMP dependent protein kinase II has a small effect on its activity, whereas the secondary phase involving Ser126 phosphorylation may generate an active form PMID: 12764134
19. Characterization of the 4q21 breakpoint revealed PRKG2 as the likely gene partner to PDGFRB in myeloproliferative disorders. PMID: 18262053
20. Results suggest that the cGK II gene on chromosome 4q21 is most likely to harbour gout disease independently of hyperuricaemia and is inherited recessively. PMID: 18678579
21. Regulation of epithelial sodium channels by cGMP/PKGII. PMID: 19359370
22. PRKG2 inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines. PMID: 19543319

Show More

Hide All

HGNC: 9416

OMIM: 601591

KEGG: hsa:5593

STRING: 9606.ENSP00000264399

UniGene: Hs.232044